0.05Open0.07Pre Close19 Volume259 Open Interest13.00Strike Price95.00Turnover160.17%IV55.73%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0590Delta0.0542Gamma167.60Leverage Ratio-0.0127Theta0.0001Rho9.90Eff Leverage0.0016Vega
Anavex Life Sciences Stock Discussion
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference
Anavex Life Sciences (Nasdaq: AVXL) announced it will present new long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial for blarcamesine in early Alzheimer's disease at the J.P. Morgan 2025 Healthcare Conference. The presentation will showcase data from up to 144 weeks of continuous treatm...
hmmmmm 🤔 looks very similar throughout the market starting at 3 pm
No comment yet